Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Behrman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|April 18, 2009
Biosimilars: considerations for an abbreviated pathwaySteven Kozlowski, Rachel Behrman
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
The New England Journal of Medicine|August 5, 2011
Developing the nation's biosimilars programSteven Kozlowski, Janet Woodcock, Karen Midthun, et al.
The New England Journal of Medicine|June 10, 2011
New FDA regulation to improve safety reporting in clinical trialsRachel Behrman Sherman, Janet Woodcock, Janet Norden, et al.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|April 18, 2009
Biosimilars: considerations for an abbreviated pathwaySteven Kozlowski, Rachel Behrman
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
The New England Journal of Medicine|August 5, 2011
Developing the nation's biosimilars programSteven Kozlowski, Janet Woodcock, Karen Midthun, et al.
The New England Journal of Medicine|June 10, 2011
New FDA regulation to improve safety reporting in clinical trialsRachel Behrman Sherman, Janet Woodcock, Janet Norden, et al.
Nature Reviews. Drug Discovery|July 20, 2007
The FDA's assessment of follow-on protein products: a historical perspectiveJanet Woodcock, Joseph Griffin, Rachel Behrman, et al.
Pageof 1